Evidence map›Paper›PMID 42469793›Full record

ArticleAlgorithms for molecular biology : AMB2026

Mutational signature refitting on sparse pan-cancer data.

Gal Gilad, Teresa M Przytycka, Roded Sharan

Abstract read
In one paragraph

Article in Algorithms for molecular biology : AMB, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Gal GiladBlavatnik School of Computer Science and AI, Tel Aviv University, Tel Aviv, 69978, Israel.
Teresa M PrzytyckaNational Library of Medicine (NLM), National Institutes of Health (NIH), Bethesda, MD, 20892, USA.
Roded SharanBlavatnik School of Computer Science and AI, Tel Aviv University, Tel Aviv, 69978, Israel. roded@tauex.tau.ac.il.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundMutational processes shape cancer genomes, leaving characteristic marks that are termed signatures. The level of activity of each such process, or its signature exposure, provides important information on the disease, improving patient stratification and the prediction of drug response. Thus, there is growing interest in developing refitting methods that accurately decipher those exposures. Previous work in this domain was unsupervised in nature, employing algebraic decomposition and probabilistic inference methods.

resultsWe present SuRe, a supervised approach to signature refitting that demonstrates superiority over current methods. SuRe leverages a neural network model to capture correlations between signature exposures in real data. We show that SuRe outperforms previous methods on sparse mutation data from both tumor-type-specific and pan-cancer data sets, with an increasing performance advantage as the data become sparser.

conclusionWe further demonstrate the model's utility in clinical settings by predicting homologous recombination deficiency in breast cancer from sparse data. Furthermore, SuRe outperforms standard methods in the unsupervised stratification of over 13,000 patients from large-scale panel sequencing cohorts, highlighting its potential for analyzing targeted sequencing data.

Indexed as

Cancer genomicsGenomic data analysisMutational signaturesSignature refittingSomatic mutations

Identifiers

PMID42469793
PMCPMC13660035

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.